Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cellsJun Shimizu, Tatsuo Shioda, Tadahiro Sasaki et al.|Scientific Reports|2022Cited by 48
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trialYoshimasa Shiraishi, Isamu Okamoto, Shogo Nomura et al.|The Lancet Respiratory Medicine|2024Cited by 43
Dengue virus type 3 infection in a traveler returning from Costa Rica to Japan in 2023Tadahiro Sasaki, Michinori Shirano, Tetsushi Goto et al.|Tropical Medicine and Health|2024Cited by 1
617P Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)H. Kikuchi, S. Oizumi, H. Mizugaki et al.|Annals of Oncology|2024Cited by 1
Author Correction: Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cellsJun Shimizu, Tatsuo Shioda, Tadahiro Sasaki et al.|Scientific Reports|2023Cited by 0